P.G. FILIPPOV

Clinical Hospital No. 6 named after G. A. Zakharyin, Penza

  Contact details:

Filippov P.G. — Head of the Neurology Department

Address: 7 Stasov St., Penza, Russian Federation, 440060, tel.: +7 (8412) 983-744, e-mail: Filippovpg@mail.ru

The purpose — to evaluate the clinical outcomes of reperfusion therapy with a Russian recombinant tissue plasminogen activator in patients with IS in the over 70 y. o. age group.

Material and methods. The analysis included 22 patients (27% males, 73% females) with IS, aged 70 to 90 y. o. (mean age 77.2 y. o.), who were treated at Clinical Hospital No. 6 named after G. A. Zakharyin, Penza, from February to October 2020. All the included patients underwent clinical, instrumental, and laboratory examination in accordance with the Protocol of reperfusion therapy for IS. On admission, all patients had a severe neurological deficit with an NIHSS score of 15-20 points and 5 points on the modified Rankin scale.

Results. All included patients suffered from hypertension, 86,3% of patients had atrial fibrillation, 9% had diabetes mellitus. The mortality rate was 9,09%. Asymptomatic hemorrhagic transformation type 1 (ECASS criteria) was reported in 3 subjects (13,6%). The proportion of patients with good functional recovery (0–2 points on the modified Rankin scale) at discharge was 27,3%. The average number of hospital stay days was 12.1.

Conclusion. Thrombolytic therapy with the Russian drug alteplase in patients with IS in the age group over 70 y. o. is safe and effective. The analyzed data allow concluding that treatment of thrombolysis with alteplase in this age group contributes to an improvement in functional outcomes and decreases mortality and the time spent in hospital.

Key words: ischemic stroke, systemic thrombolytic therapy, alteplase.

REFERENCES

1. Gusev E.I. et al. Klinicheskie rekomendatsii po provedeniyu tromboliticheskoy terapii u patsientov s ishemicheskim insul’tom [Clinical guidelines for thrombolytic therapy in patients with ischemic stroke]. Moscow, 2015.
2. Piradov M.A., Maksimova M.Yu., Tanashyan M.M. Insul’t: poshagovaya instruktsiya [Stroke: step by step instructions], 2019.
3. Satue E. et al. Incidence and risk conditions of ischemic stroke in older adults. Acta Neurologica Scandinavica, 2016, vol. 134 (4), pp. 250–257.
4. Hacke W. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). Jama, 1995, vol. 274 (13), pp. 1017–1025.
5. Hacke W. et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). The Lancet, 1998, vol. 352 (9136), pp. 1245-1251.
6. Clark W.M. et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. Jama, 1999, vol. 282 (21), pp. 2019–2026.
7. Greshman G., Alexander D.J.S. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasogen activator for acute ischemic stroke, 1997, vol. 28 (15), pp. 1522–1526.
8. Bluhmki E. et al. Alteplase for acute ischemic stroke in patients aged > 80 years: pooled analyses of individual patient data. Stroke, 2020, vol. 51 (8), pp. 2322–2331.
9. Shamalov N.A., Khasanova D.R., Stakhovskaya L.V. et al. Reperfuzionnaya terapiya ishemicheskogo insul’ta: klinicheskiy protokol [Reperfusion therapy of ischemic stroke: clinical protocol]. Moscow: MEDpress-inform, 2019.
10. Kokorin V.A. et al. Comparative study of the efficacy and safety of domestic recombinant tissue plasminogen activator Reveliza® in patients with myocardial infarction. Terapiya, 2019, vol. 5, no. 2, pp. 42–57 (in Russ.).
11. Gusarova V.D. et al. Physicochemical and biological properties of biosimilar and reference preparations of tissue plasminogen activator. BIO preparaty. Profilaktika, diagnostika, lechenie, 2019, vol. 19, no. 1 (in Russ.).
12. Pravila provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza. Utverzhdeny resheniem Soveta EEK 16.11.2016 no. 89 [Rules for conducting research on biological medicinal products of the Eurasian Economic Union. Approved by the decision of the EEC Council on November 16, 2016 No. 89], accessed on: 12.08.2021, available at: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89